92% RFS at 2 Years: PD-1 Immunotherapy for MMRd / MSI-H Tumors at AACR 2025 AACR 2 Mins Read A New Approach to MMRd/MSI-H Tumors At the AACR Annual Meeting 2025 in Chicago, Dr. Andrea Cercek presented compelling data…
